BioCryst Pharmaceuticals has secured Japanese approval for once-daily ORLADEYO, or berotralstat, to prevent hereditary angioedema attacks in children aged two to under 12 years, extending the drug into an age group that has traditionally relied heavily on injectable preventive therapies. Japan’s Ministry of Health, Labor and Welfare authorized the pediatric granule formulation following encouraging data from the ongoing APeX-P study, while BioCryst plans to launch the treatment after completion of Japan’s National Health Insurance reimbursement pricing process.
The regulatory expansion arrives as ORLADEYO becomes an increasingly important commercial asset for BioCryst Pharmaceuticals. Second-quarter 2026 ORLADEYO revenue reached $158.2 million, and the company continues to forecast between $625 million and $645 million in global product revenue for the full year, making pediatric expansion potentially valuable even if younger hereditary angioedema patients represent a relatively small population.
Japan approval extends once-daily hereditary angioedema prevention to children under 12
The latest decision makes ORLADEYO the first and only targeted oral prophylactic therapy available in Japan for hereditary angioedema patients aged two years and older. The drug was already approved in Japan in January 2021 as a capsule for adults and adolescents aged 12 years and above, meaning the new authorization closes much of the remaining pediatric age gap.
Hereditary angioedema is a rare genetic disorder characterized by unpredictable episodes of severe swelling that can affect the face, limbs, gastrointestinal tract and airway. Because attacks can occur without warning and potentially become life-threatening when the airway is involved, long-term prophylactic treatment is intended to reduce attack frequency rather than simply respond once symptoms begin.
Treatment burden can be particularly significant in young children. BioCryst Pharmaceuticals said preventive treatment has traditionally involved injections for pediatric patients, creating additional challenges for both children and caregivers. The Japanese formulation is designed as granules that can be poured directly into the mouth and swallowed with water or milk, or sprinkled over a spoonful of soft, non-acidic food.
That administration profile could become an important point of differentiation. ORLADEYO inhibits plasma kallikrein, an enzyme involved in the pathway that drives swelling in hereditary angioedema, and requires only one oral dose per day. A convenient oral preventive therapy could potentially reduce resistance to chronic prophylaxis among families that would otherwise need to manage recurring injections.
OrphanPacific is BioCryst Pharmaceuticals’ representative partner in Japan and holds the marketing authorization. Commercial availability will follow completion of the country’s National Health Insurance pricing process, making reimbursement the next practical milestone before physicians can begin prescribing the pediatric formulation broadly.
APeX-P data show sustained reductions in attacks across one year of treatment
Japan’s regulatory decision was supported by interim findings from APeX-P, an ongoing open-label study evaluating the pharmacokinetics, safety and efficacy of ORLADEYO in hereditary angioedema patients aged two to under 12 years with C1-inhibitor deficiency. Twenty-nine participants were assigned to four dosing cohorts according to body weight after initially undergoing 12 weeks of standard-of-care treatment.
Updated 48-week results presented in June showed that the median adjusted rate of attacks requiring on-demand treatment declined from 0.691 attacks per month during the standard-of-care period to 0.169 attacks per month during ORLADEYO treatment. The number of attacks requiring professional medical care also fell sharply, from 22 during the 12-week standard-of-care period to three during the first comparable 12 weeks of ORLADEYO treatment. No attacks requiring professional care were recorded during weeks 37 through 48 in the reported analysis.
Earlier one-year findings similarly showed that 65.5% of participants were attack-free at month one and 70.4% were attack-free at month 12. The median monthly attack rate reached zero in the first month and remained at zero for 11 of the 12 reported treatment months, while 93.1% of participants completed at least 48 weeks of therapy.
These findings are particularly relevant because hereditary angioedema frequently becomes clinically apparent early in childhood. Within APeX-P, the median age at diagnosis was two years, while more than 82% of participants had experienced symptoms before reaching six years of age. That reinforces the rationale for making preventive therapy available well before adolescence rather than waiting until patients qualify for formulations designed for older age groups.
The safety findings have so far remained broadly consistent with the known profile of berotralstat. BioCryst Pharmaceuticals reported no new safety signals in the pediatric study, with nasopharyngitis the most commonly reported treatment-emergent adverse event. The study nevertheless has limitations, including its small sample size, open-label design and absence of a randomized comparator group, meaning the accumulating long-term experience will remain important.
Pediatric expansion could deepen ORLADEYO’s position in a growing global franchise
Japan is the second market to approve the pediatric oral formulation. The United States Food and Drug Administration authorized ORLADEYO pellets for children aged two to under 12 years in December 2025, and BioCryst Pharmaceuticals began shipping the pediatric product to United States patients during the week of August 3, 2026. The company reported 47 pediatric prescriptions year to date as of its second-quarter update, with more than half having already completed prior authorization and a high approval rate among those cases.
Further geographic expansion is also under way. BioCryst Pharmaceuticals has submitted applications seeking pediatric ORLADEYO approval to the European Medicines Agency and Health Canada and plans additional regulatory filings in other territories. The adult and adolescent formulation is already approved in more than 45 countries, giving the company an established commercial footprint that could facilitate broader pediatric launches.
The financial backdrop makes those incremental expansions increasingly meaningful. ORLADEYO generated $158.2 million in second-quarter 2026 revenue and $306.5 million during the first six months of the year. On a comparable basis excluding European revenue following the sale of BioCryst Pharmaceuticals’ European ORLADEYO business, second-quarter product revenue grew about 10% from the prior year.
BioCryst Pharmaceuticals maintained its 2026 ORLADEYO revenue forecast of $625 million to $645 million while raising total company revenue guidance to between $690 million and $715 million. The company also recorded a second-quarter operating profit of $98.5 million and ended June with approximately $354 million in cash, investments and restricted cash, demonstrating how far ORLADEYO has progressed from a launch-stage rare-disease medicine toward a substantial commercial franchise.
The company is simultaneously building a next-generation hereditary angioedema portfolio around navenibart, a long-acting plasma kallikrein inhibitor acquired through BioCryst Pharmaceuticals’ purchase of Astria Therapeutics. Enrollment in the pivotal ALPHA-ORBIT study was completed in June, with top-line results from every-three-month and every-six-month dosing cohorts expected in the third quarter of 2027.
That creates an unusual strategic dynamic in which BioCryst Pharmaceuticals could eventually offer both a convenient daily oral medicine and a highly infrequent injectable option. Rather than making ORLADEYO obsolete, successful navenibart development could potentially broaden BioCryst Pharmaceuticals’ ability to address different patient preferences within the same hereditary angioedema market.
BioCryst Pharmaceuticals shares show muted reaction as investors focus on broader execution
BioCryst Pharmaceuticals shares traded around $9.78 during the August 25 session, modestly above the previous close of $9.68 following the Japanese announcement. The stock remains below its 52-week high of $11.22 but substantially above its 52-week low of $6.00, suggesting that investors are assigning meaningful value to ORLADEYO growth and the expanded hereditary angioedema pipeline while remaining cautious about execution.
Wall Street sentiment is generally constructive. StockAnalysis reported a Strong Buy consensus among 11 analysts with an average price target of $20.82, while other aggregators show a somewhat more conservative mix of buy and hold recommendations. Price targets are inherently uncertain, but the divergence between the prevailing share price and many analyst targets indicates that expectations for future ORLADEYO cash generation and navenibart development remain a major part of the investment thesis.
The Japanese pediatric approval is unlikely to transform BioCryst Pharmaceuticals’ revenue trajectory by itself. Its importance lies in steadily widening ORLADEYO’s addressable population, extending the product lifecycle and strengthening the company’s position across age groups as hereditary angioedema treatment becomes increasingly focused on convenience and prevention.
If BioCryst Pharmaceuticals can translate United States pediatric demand into similar adoption internationally while maintaining adult ORLADEYO growth, the franchise could continue expanding even before navenibart reaches a regulatory decision. Japan therefore represents another incremental but strategically useful step in turning ORLADEYO into a broader global hereditary angioedema platform.
